Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Austria-based antibody engineering company F-star has raised E3 million from Novo in a second closing of its series A financing round, originally co-led by Aescap Venture and Atlas Venture.
Subscribe to our email newsletter
Combined with existing cash and commitments, the additional funds raised in this round will allow F-star to further speed up the development of its unique modular antibody technology platform and to devote additional resources to the development of its proprietary product portfolio, as well as industry collaborations.
After this second closing, the amount raised in the series A round increases to E9 million. In total, F-star has raised E13 million since inception in 2006.
Kim Dueholm, a partner in Novo said: “F-star has managed to build a strong intellectual property position in the exciting field of novel antibody scaffolds. This strong proprietary position, the unique properties of F-star’s proprietary scaffold (Fcab), and the strength of F-star’s investor base make F-star a perfect addition to Novo’s portfolio.”